TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
TG Therapeutics (NASDAQ:TGTX) will hold a conference call on Monday, November 3, 2025 at 8:30 AM ET to discuss third quarter 2025 financial results and provide a business outlook for the remainder of 2025.
Rhea-AI Summary
TG Therapeutics (NASDAQ:TGTX) will hold a conference call on Monday, November 3, 2025 at 8:30 AM ET to discuss third quarter 2025 financial results and provide a business outlook for the remainder of 2025.
Michael S. Weiss, Chairman and CEO, will host. The company will issue a press release with financial results prior to the call. Investors can join by phone (1-877-407-8029 U.S.; 1-201-689-8029 outside the U.S.) or listen via a live webcast on the Investors & Media Events page at www.tgtherapeutics.com. An audio replay will be available on the company website for 30 days after the call.
Positive
- None.
Negative
- None.
Details
News Market Reaction – TGTX
On Oct 31, the day this news came out, TGTX closed 2.23% above the previous close.
Data tracked by StockTitan Argus for the Oct 31 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call to be Held Monday, November 3, 2025, at 8:30 am ET
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to discuss results for the third quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.